Alzheimer’s disease drug market is on the curvature stage. Since 2003, there is not any single “magic bullet” launched in the market to prevent or cure it. However, all current marketed products are going to be generic in the next 3-4 years. There are high unmet medical needs. The current unmet needs represent a huge opportunity for pharmaceutical companies which are developing targeted novel therapies. If successful, they will be in a position to command premium prices and tap the existing opportunity. Lot of drugs has failed in Phase III stage thus putting a greater impact on Alzheimer’s disease drug market. From the year 2009 Alzheimer’s disease drug market is declining and it is expected to fall till 2016. But with the expected launch of some Alzheimer’s drugs from the year 2017 onwards, Alzheimer’s disease drug market is expected to revive in the coming years. However due to absence of exact potential drugs there will always remain a huge Unmet Alzheimer’s Drug Market. For the year 2018 Alzheimer’s Disease Drug Market will be just 10% of Unmet Alzheimer’s Disease Drug Market. Renub Research study titled “Alzheimer’s Pipeline Drugs Review, Alzheimer’s Disease Drug Market & Forecast – Global Analysis” provides a comprehensive assessment of the fast-evolving, high-growth Global Alzheimer’s Disease Market. This 110 page report with 29 Figures and 11 Tables studies the Global Alzheimer’s Disease Drug Market. Present & Pipeline Drugs Studied in this Report 1. Namenda2. Ebixa3. Axura4. Aricept5. Nootropil6. Exelon7. Memary8. Solanezumab9. LuAe58054 This report contains 10 chapters. (Chapter 1): Executive Summary (Chapter 2): This Chapter is divided into 2 parts A. Alzheimer’s Disease Drug Market & Forecast data available from 2003 to 2018 B. Unmet Alzheimer’s Disease Drug Market & Forecast (Market Potential) data available from 2010 to 2018. (Unmet market is the potential market which could have been achieved if right drug have been introduced in the market) (Chapter 3): This chapter talks about drugs which has failed while in Clinical trials (Chapter 4): This chapter provides Market Share of Alzheimer’s Disease Drug from 2003 to 2018. All the 9 Alzheimer’s drug mentioned above have been covered in this chapter. (Chapter 5): This chapter talks about Alzheimer’s Drugs performance. All important drugs mentioned above past, present & future market data available from 2003 to 2018. (Chapter 6): Pipeline drugs (Solanezumab, LuAE58054, Gantenerumab, Crenezumab, TRx0237 (LMTX), MK-8931, ABT-126, AZD-1446) have been analyzed in this chapter. All drugs have been analyzed from 5 view points: A. Clinical Development StageB. Pipeline Drug Sales PerformanceC. Recent Clinical DevelopmentD. Different Companies DealE. Investment (Chapter 7): This chapter speaks of Alzheimer’s Drugs Company deals in four areas A. Strategic Alliances in Alzheimer’s Disease Drug MarketB. Licensing Agreement in Alzheimer’s Disease Drug MarketC. Collaboration Deal in Alzheimer’s Disease Drug MarketD. Merger & Acquisition in Alzheimer’s Disease Drug Market (Chapter 8): This chapter studies Funding in Alzheimer’s Disease Drugs Research. We have covered 5 institutes which provides fund for the research. A. National Institute of HealthB. Alzheimer's AssociationC. Cure Alzheimer’s FundD. Alzheimer’s Drug Discovery FoundationE. BrightFocus Foundation [formerly American Health Assistance Foundation (AHAF)] (Chapter 9): This chapter studies Growth Factors Driving the Alzheimer’s Disease Drug Market. (Chapter 10): This chapter studies Challenges/Hindrances faced by Alzheimer’s Disease Drug Market.
This report is built using data and information sourced from proprietary databases, secondary research and in-house analysis by Renub Research team of industry experts. Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Government Agencies, Magazines, Newspapers, Trade associations, Books, Industry Portals, Industry Associations and access to more than 100 paid databases.
Click here to view the report details: http://renub.com/report/alzheimers-pipeline-drugs-review-alzheimers-disease-drug-market-forecast---global-analysis-127
For more information visit: http://www.renub.com/
Andy HillSr. Manager - Publisher RelationSales & Marketing DivRenub ResearchEmail: email@example.com Phone: +1-678-302-0700 (USA) +91-120-254-5750 (India)Web: http://www.renub.com/
Renub Research is a leading
Management Consultancy and Market Research Company. We have more than 10
years of experience in Research, Survey and Consulting. We provide wide
range of business research solutions that helps companies in making
better business decisions. We partner with clients in all sectors and
regions to identify their highest-value opportunities, address their
most critical challenges, and transform their businesses.